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Antibody arrays were developed to probe a monoclonal antibody’s three-dimensional
structure (3-D structure). Peptides with overlapping regions were designed to cover the
whole mAb light chain and heavy chain, respectively, and used to generate polyclonal
antibodies after the conjugation of the peptides to a carrier protein, KLH. It was shown
that good peptide specificity was achieved from the antibodies generated. Using more
than 30 different polyclonal antibodies to measure the surface epitope distribution, it
was shown that the mAb antibody array can detect epitope exposure as low as 0.1%
of defined mAb populations. This ELISA-based analysis of mAb epitope exposure can be
considered as a measurement of “conformational impurity” in biologics development,
similar to the analysis of other product-related impurities such as different forms of
glycosylation, deamidation, and oxidation. This analysis of “conformational impurity” could
provide valuable information on the mAb conformational comparability for biosimilar mAbs
as well as novel mAbs, especially in the area of protein immunogenicity. Furthermore,
stability studies indicated that there are several conformational “hot spots” in many
mAbs tested, especially in the hinge region. This antibody array technology can be used
for novel mAb Higher Order Structure (HOS) analysis during process and formulation
development. Another important area of application is for biosimilar mAb development
where the innovator molecule and biosimilar molecule could be compared based on their
systemic “fingerprint” from the 30 plus antibodies.
Keywords: monoclonal antibody, Higher Order Structure, ELISA, biosimilars, comparability, conformational
stability
INTRODUCTION
Protein structure is the foundation of a protein’s func-
tion. Numerous studies have demonstrated that protein three-
dimensional structure (3-D structure) (Higher Order Structure
or HOS) is critical for its biological function because the func-
tions of all proteins rely on the precise spatial positioning of
several functional groups with respect to each other (Kaiser and
Kezdy, 1983). In biologics development, in addition to the impor-
tance of protein function, drug safety is also a major concern
and protein immunogenicity is the focus of safety (Hermeling
et al., 2004, 2005; Jiskoot et al., 2009). Throughout the history
of biologics development, the immunogenicity of biologics has
been reduced significantly. In the earlier days of biologics devel-
opment, proteins of animal origin were used as therapeutics such
as equine antisera, porcine/bovine insulin, this often resulted in
significant immune response. Later on, human derived proteins
were used for disease treatment such as human growth hormone
and Factor VIII; however, the limitation of the human source lim-
ited the wide use of such biologics. Starting in the 1980s, with
the development of biotechnology, many biologics could be pro-
duced efficiently in bacteria and other cultured cells, hastening
the development of the biotechnology industry.
There are several consequences of immunogenicity in biolog-
ics. One of the major effects is a loss of efficacy because the
antibodies generated against the biologics in turn will neutralize
the biologics; more than a dozen cases of biologics have been
reported showing this effect. A second consequence of anti-drug
antibodies can be the enhancement of drug efficacy, sometimes
this enhancement of efficacy could also cause a negative effect in
the patient because it causes a biological imbalance for the home-
ostasis of the body. A third consequence of anti-drug antibodies
can include the neutralization of endogenous proteins that share
similar molecular structure to the biologic. Immunogenicity can
also cause general immune effects such as allergy, anaphylaxis and
serum sickness etc., and finally it is also possible that the anti-drug
antibodies will not have any observed consequences. While the
factors that influence the immunogenicity of biologics are many,
they can be divided into two categories: (1) Product-related. This
includes the sequence variation of the biologics, different impu-
rity and contamination, product modification, and formulation.
(2) Treatment related. This includes the application route, length
of treatment, dose, and nature of the disease and the status of the
patient.
In the past decade, great strides have been made in ana-
lytical technologies for the analysis of protein structure espe-
cially in the analysis of protein primary and secondary structure
and post-translational modification such as glycosylation (which
is closely related to a protein’s function and immunogenicity
potential). However, one area where more development is needed
for an accurate and efficient structural analysis is determination
of the 3-D structure (HOS) of biologics. In the recently pub-
lished guidelines for biosimilar development, the US Food and
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Drug Administration (FDA) acknowledged that “a protein’s 3-D
structure is important but difficult to define using the current
analytical technologies” (US Food and Drug Administration,
2012). There are several reasons why the analysis of protein HOS
is such a challenge. On one side, it is the inherent complex-
ity of the protein HOS. Many studies indicated that, different
from a protein’s primary and secondary structure, a protein’s
HOS could assume multiple conformations and the conforma-
tion is more dynamic than protein’s secondary structure (James
et al., 2003; Nobeli et al., 2009; Franco, 2011). This multiplicity
makes some of the current technologies less informative in HOS
analysis (Dyson and Wright, 1993). For example, CD (Circular
Dichroism), Fluorescence and NMR have been used to analyze
protein HOS, however, these techniques are not sensitive enough
to detect many regional or minor but important conformational
changes. Furthermore, the signal obtained by these technologies
is an average of the whole population. They cannot reveal specific
changes in a sub-population or regional changes in a molecule
and it is this detailed information that is critical for an under-
standing of the function and potential immunogenicity of the
biologics.
Given the limitations in the current analytical technologies
for protein HOS analysis, efforts have been made to develop
alternative technologies that could more accurately measure a
protein’s HOS. Hydrogen-Deuterium Exchange (HDX) is a tech-
nology that has been available for more than 20 years (Houde
et al., 2009, 2010, 2011; Wei et al., 2012). It has gained momen-
tum recently for the analysis of protein HOS due to improve-
ments in mass spectrometry and software for data processing
(Jacob and Engen, 2012; Pascal et al., 2012; Xiong et al., 2012).
However, there are some limitations for HDX technology, one
of the major challenges is its technological complexity. Extensive
Mass Spectrometry expertise is needed to carry out the analy-
sis and data processing. These factors limit its use as a routine
assay in biologics process and formulation development or for
comparability studies. Another limitation to HDX is assay accu-
racy. Because of the complexity of the process that involves
proteolytic digestion, chromatography, and MS for protein iden-
tification, a highly reproducible result is often difficult to obtain.
Therefore, a more sensitive and accurate technology is desir-
able in the area of protein HOS analysis. Recently, aptamers
has been used to study therapeutic protein structural changes
with some very interesting findings; however, more studies are
needed to demonstrate the value of this novel technology in
monoclonal antibody conformational analysis (Sominskaya et al.,
1992).
In immunology, it is known that 5–6 amino acids are ade-
quate to form an epitope for antibody generation; there are also
reports of 3–4 amino acids that can define an epitope (Nestor,
2009; Zichel et al., 2012). The current study reports an anti-
body array-based approach to measure monoclonal antibody
surface epitope distribution that will reflect the protein’s HOS.
First, peptides with overlapping regions were designed to cover
the whole sequence of a protein. For a monoclonal antibody,
a total of 34 different peptides were used to cover the mAb
light chain and heavy chain, respectively. Second, all the pep-
tides are conjugated to a carrier protein such as KLH (Keyhole
Limpet Hemocyanin) to increase the peptide immunogenic-
ity and retention time in the host. Another consideration in
the development of the antibody is the length of the peptides.
Previous studies indicated that peptides as short as 11 amino
acids could form secondary structure such as α-helix (Dyson
and Wright, 1991; Thomas et al., 2006; Maupetit et al., 2009).
During the development of the antibody arrays, peptides with
amino acid length between 25 and 30 were designed that, in the-
ory, would allow the formation of some secondary structure such
as α-helix and β-sheet. The intention was to generate antibodies
that also react to some of the secondary structure features of the
protein.
Since the principle of the antibody array technology is based
on epitope recognition, it was expected that the signal obtained
from this antibody-based measurement would measure struc-
tural features at the molecular level (Shon et al., 1991), and
more importantly, because each peptide corresponds to a certain
region of the protein, if the peptide-derived antibody demon-
strates good specificity, this approach would allow the regional
(local) assignment of the recognized change. This report is
the summary of the development of multiple antibody arrays
toward many best-selling monoclonal antibody therapeutics cur-
rently on the market and also one set of antibody arrays for
novel mAb development. It was shown that sensitive and accu-
rate information could be obtained using this antibody-based
approach, and this information could be used for the develop-
ment of novel therapeutic mAbs as well as biosimilar mAbs,
case studies were presented in these two important application
areas.
MATERIALS ANDMETHODS
REAGENTS
All the chemicals were purchased from Sigma-Aldrich (St. Louis,
Missouri). 96-well microplates were purchased from Corning Co.
(Corning, New York). Streptavidin-HRP conjugate and biotin
labeling kits were obtained from Thermo Scientific (Rockford,
Illinois).
ANTIBODIES AND ELISA KITS
All the antibodies and ELISA kits used in this study were products
of Array Bridge Inc. (St. Louis, Missouri). Polyclonal antibod-
ies against the peptides were produced in New Zealand White
Rabbits. For the sandwich ELISA, antibodies against each region
of themAbmolecule were coated on 96-well plates with each anti-
body coating a column in row B through G. In each column of
the coated plates, the upper three wells (B, C, and D) were incu-
bated with a reference mAb such as an innovator mAb (marketed
mAb) in triplicate, and the lower three wells (E, F, and G) were
incubated with a biosimilar mAb candidate in triplicate. A biotin-
labeled rabbit anti-human IgG antibody was used to detect the
mAb-peptide antibody complex, and streptavidin-HRP was used
to detect the complex formed by anti-human IgG-mAb-peptide
antibody. The signal strength of the sandwich ELISA depends on
the relative epitope exposure of the mAb in each region. If there
are more epitopes from the mAb that could be recognized by the
peptide-derived antibody, a stronger signal will be produced and
vice-versa.
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SAMPLE TREATMENT
For urea-denatured monoclonal antibodies, urea at a final
concentration of 8M was added to a 10mg/ml mAb solu-
tion and incubated overnight at 4◦C. The mAb solution was
subsequently diluted to 5μg/ml for ELISA analysis. For heat
treatment, mAbs at 2mg/ml in PBS were treated at indi-
cated temperature overnight and then diluted to 5μg/ml for
analysis.
For the sandwich ELISA, six rows of anti-peptide antibodies
were coated in 96-well plates from row B–G. For comparability
studies, the first three rows (B, C, D) were used for reference
mAb, typically the innovator mAb (marketed product), while
rows E, F, and G were used for the analysis of the biosimilar
mAb or mAb under various treatment. For reporting antibody, a
polyclonal anti-human IgG antibody (developed by Array Bridge
Inc.) was used which detected the capturing antibody-mAb com-
plex. The reporting antibody was labeled with biotin which in
turn forms a complex with streptavidin-HRP conjugate, TMB
(3,3′, 5,5′-tetramethylbenzidine) was used as substrate for the
HRP enzyme activity assay. Following a short development time
to allow color formation from the HRP enzymatic activity, an
equal volume of 1M sulfuric acid was added to stop the reaction.
A spectrophotometric plate reader (SpectraMax M3, Molecular
Devices, Sunnyvale CA) was used to measure the color change at
450 nm.
RESULTS AND DISCUSSIONS
ANTIBODY SPECIFICITY
One of the criteria required to develop a successful antibody
array is the capability to probe regional changes in biologics
molecules. To achieve this goal, the antibody specificity is critical.
In Figure 1, each of the 30 different anti-peptide antibodies were
probed with each of the corresponding 30 peptides in a pairwise
analysis, i.e., each peptide was analyzed by all the 30 different anti-
bodies and each antibody was probed with 30 different peptides.
The results showed that good antibody specificity was achieved.
There were a few cases of cross-reactivity from the 30 peptide and
30 antibody cross-testing (900 data points), but the overall speci-
ficity was good, suggesting that these peptide-derived antibodies
could be used to probe regional changes in the mAb structure.
In this pairwise testing, the main cross-reactivity occurred on the
two side of the diagonal line; this was actually expected from
the special design of the antibody array. In the antibody array
design, peptides covering the entire monoclonal antibody light
chain and heavy chain were synthesized with overlapping regions,
therefore, each peptide will have two overlapping regions from
its N-terminal and C-terminal ends, respectively, only the pep-
tide corresponding to the very ends of the mAb light chain and
heavy chain will have one overlapping region. Because of this
special design, the polyclonal antibodies generated from one pep-
tide could potentially recognize the adjacent peptides, and for
the same reason, the antibodies generated from the two adjacent
peptides could also recognize the peptide in the middle.
SENSITIVITY OF THE ASSAY
Another important parameter for the antibody array technology
is the sensitivity of the assay. As a useful analytical technology, it
FIGURE 1 | Specificity testing of the array antibodies. 30 antibodies
generated against 30 different peptides derived from monoclonal antibody
on the market were tested for their specificity in Direct ELISA. Each peptide
was coated onto a 96-well plate, after blocking with 1% BSA in PBS-T
(phosphate-buffered saline with 0.1% Tween-20), all the 30 different
antibodies were tested against each peptide, and a total of 900
combinations will be produced. The peptide-antibody complex was further
recognized by goat anti-rabbit IgG-HRP conjugate, and TMB was used as
HRP substrate for color development, triplicate assays were used for the
analysis.
needs to detect either regional changes of the whole mAb popula-
tion or changes in a sub-population which could be closely related
to the mAb’s efficacy and safety. To estimate the sensitivity of
the technology, an artificial sample with unfolded mAb molecule
needs to be generated. In the sensitivity testing, unfolded mAb
was induced by 8M urea and spiked into native mAb at 0, 0.1,
0.2, and 0.5%, respectively; it was demonstrated that as low as
0.1% spike will result in a significant increase of ELISA read-
ing, suggesting that at least 0.1% novel epitope exposure could
be detected and quantified by the antibody array (Figures 2A,B).
Compared with other analytical methods used for mAb HOS
analysis, antibody array technology is a more sensitive method.
More importantly, the antibody array method is an accurate ana-
lytical method with variation typically less than 15%. Figure 2C
is an example of building a standard curve of epitope exposure
using 8M urea-treated mAb, as shown here, for each region of
the mAb, a standard curve could be built to accurately measure
the epitope exposure.
One of the advantages for antibody array technology is that
the sensitivity of the method can also be increased with increased
mAb concentration. Figure 3 show the assay results with mAb
concentration at 0.5, 5, and 50μg/ml, respectively. As can be seen,
the sensitivity of the ELISA increases in proportion to the con-
centration of the testing mAb. For a typical assay, 5μg/ml mAb is
recommended. It is important to point out that because of the
large size of monoclonal antibodies and the complex structure
of the molecule, many of the linear epitopes the antibody array
raised against are not exposed on the surface of the molecule,
therefore, at any time, the antibody array can only detect a sub-
population of the mAb for which the corresponding epitopes
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FIGURE 2 | (A) Sensitivity of the antibody array ELISA for mAb surface
epitope exposure in the variable region.A monoclonal antibody under clinical
development was treated with 8M urea and spiked into the same native
mAb at 0, 0.1, 0.2, and 0.5%, respectively. Sandwich ELISA was used to
measure the surface epitope exposure of each mAb samples. A final mAb
concentration of 5μg/ml was used for the analysis. (B) Sensitivity of the
antibody array ELISA for mAb surface epitope exposure in the constant
region. Same conditions as in (A)were used for the testing except the
antibodies tested were against the constant regions of the mAb. (C)
Quantitation of Epitope Exposure using the Antibody Array ELISA Standard
Curve. For the quantitative measurement of surface epitope exposure in
different regions of the mAb, a standard curve could be generated with the
different levels of unfolded mAb induced from 8m urea treatment.
FIGURE 3 | Sensitivity of the antibody array ELISA at different mAb
concentrations. The sensitivity of the antibody array ELISA could be
adjusted from the concentration of mAb used. If the intension is to detect
an even smaller population of mAb with defined epitope exposure, a higher
mAb concentration could be used such as 50μg/ml. On the other hand, if it
is a preliminary testing of surface epitope exposure, a low mAb
concentration could be used such as 0.5μg/ml. The standard
recommended mAb concentration for testing is 5μg/ml.
are exposed on the surface. This sub-population can be consid-
ered as a “conformational impurity” if the majority of the mAb
has the epitopes buried inside. It is believed that this measure-
ment of the “conformational impurity” will provide interesting
information on how comparable the biosimilar mAbs vs. inno-
vator molecules or how two batches of the same mAb match
up conformationally in change control during novel mAb devel-
opment. It is also believed that this “conformational impurity”
may also be related to the mAb immunogenicity potential and/or
its efficacy. For example, in the biosimilar mAb development,
one can assume that corresponding to each region of the mAb;
the innovator molecule has a sub-population of molecules with
epitopes exposed on the surface. This sub-population can be con-
sidered as clinically tolerant “conformational impurity.” During
the development of biosimilar molecules, the more epitopes
exposed from this region, the more “conformational impurity”
will exist. Throughout the whole molecule, if the “conforma-
tional impurity” breaks an immunological tolerant threshold,
immunogenicity may occur. Currently it is not possible to quan-
tify the relative risk these “conformational impurities” will bring
to the biosimilar molecule, but one can infer that the more epi-
topes exposed in the biosimilar molecule as compared to the
corresponding innovator mAb, the more risk it will bring to the
biosimilar molecule. With the capability of the antibody arrays to
detect regional “conformational impurities” for any mAb under
development, it is possible to implement this technology as one
of the selection methods, together with bioassay, stability testing
and glycosylation, to select cell line(s) that have molecular char-
acteristics as close to the innovator mAb as possible including the
“conformational impurity” profile to ensure a successful effort
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FIGURE 4 | (A) Stability testing of mAbs under clinical development, the
variable region. A mAb under clinical development was treated at different
temperature as indicated overnight at 1mg/ml, and the samples were
diluted to 5μg/ml to test the surface epitope exposure for the whole
molecule. (B) Stability testing of mabs under clinical development, the
constant region. the condition is the same as in (A) except the testing are
for the mAb constant regions.
in biosimilar development. On the other hand, in novel mAb
development, the antibody array technology can also be used for
comparability studies in both process development and formula-
tion development as well as in change controls to ensure that the
mAbs produced bear similar “conformational impurity” profile.
Another point to make about this ELISA-based assay is that
the signals detected may not have a linear relationship with the
content of the “conformational impurity.” This is mainly due to
the nature of the ELISA assay. As we know, ELISA standard curve
is a sigmoidal curve, it is only in the middle of the curve that some
linear relationship could be achieved; therefore, it is important to
bear this in mind when interpreting the antibody array findings.
Sometimes, a 25% increase in the ELISA signalmay reflect a 100%
FIGURE 5 | (A) Antibody array ELISA analysis of seven marketed mAbs,
variable region. Seven mAbs on the market were tested for their surface
epitope exposure using specific antibody sets prepared against the
corresponding mAb variable region. (B) Antibody array ELISA analysis of
seven marketed mAbs, constant region. Because all the mAbs on the
market have highly homologous constant region with more than 95%
amino acid identity, a single set of antibody raised against Herceptin
constant region was used for the analysis of surface epitope exposure of all
the seven mAbs on the market.
increase in the “conformational impurity” as was shown by the
spiking test in Figure 2 using 8 M-urea unfolded mAb.
STABILITY TESTING
During biologics development, molecular stability is a major
concern because of the many known pathways to protein degra-
dation. Examples of protein degradation pathways that may lead
to the instability of the biologics under development are protein
deamidation, oxidation, fragmentation and disulfide bond mis-
formation, therefore, formulation development to stabilize the
protein is one of the most important aspects of biologics devel-
opment. Here the “conformational impurity” that is measured
with antibody array can also be considered as a form of “protein
degradation” at higher structural level. Another important appli-
cation for antibody array technology is in mAb stability testing.
Figures 4A,B shows the analysis of a mAb under clinical devel-
opment that was treated under different temperatures. As can be
seen from the figures, different regions of the mAb responded to
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FIGURE 6 | (A) Avastin variable region profile analyzed with antibody array
ELISA. A sequence-specific set of antibodies against Avastin variable region
were used for the analysis of surface epitope exposure. (B) Avastin
constant region profile analyzed with antibody array ELISA. The common
set of antibodies designed against the Herceptin constant region were
used for the analysis of surface epitope exposure.
temperature differently. Some of the more sensitive regions of the
mAb include CDR2 of the light chain, the joint region of the light
chain Fv and Fc domains, and more drastically in the mAb hinge
region. Previous studies have demonstrated that the mAb hinge
region structure is closely related to its biological function (Klein
et al., 1981).
the sensitivity to detect regional changes for as low as 0.1% of
new epitope exposure and provide a systematic coverage for the
whole molecule. Since this is an ELISA-based assay, changes in
specific regions can also be quantified. In summary, this tech-
nology could provide detailed information for the evaluation of
biosimilar mAb conformational comparability.
For currently marketed mAbs, the constant regions display
greater than 95% sequence identity and thus, are difficult to dis-
tinguish by analytical methods (Wang et al., 2009). One of the
interesting observations in the analysis of reference standards for
biosimilar mAbs is that when seven of the marketed mAbs were
analyzed using the antibody array ELISA, each mAb displayed a
unique and different profile (Figures 5A,B), indicating that there
are sequence-independent factors that play an important role in
the mAb HOS. There could be many factors contributing to the
unique profile in the constant region for each of the mAbs tested.
One factor is the different CHO cell lines used for the production
of different mAbs. It is known that different clones of the same
gene in the same cell line could produce mAbs with very different
properties such as molecular stability, glycosylation patterns etc.
Other likely factors include differences in mAb purification and
formulation.
Figures 6A,B are a close up analysis of one of the most widely
developed biosimilar candidates, Avastin. As can be seen, different
regions of the molecule respond to the antibody array differ-
ently, suggesting different epitope distribution from these regions.
However, it is important to point out that for multiple batches of
the same mAb, most of the regions respond to the antibody array
similarly, indicating similar epitope exposure population from
batch to batch. On the other hand, we have also seen a few regions
that showed batch variation for certain mAbs on the market (data
not shown).
BIOSIMILAR mAbs CONFORMATIONAL COMPARABILITY
The antibody array technology described in this report has been
used by many of the major biosimilar mAb developers in the
world and assay results that are available could be categorized into
three groups. In the first group minor conformational differences
between the innovator molecule and the biosimilar candidates
were detected, the majority of the biosimilar mAbs tested fell
into this group. In this group, usually just one or two regions of
the biosimilar mAb show differences compared with the inno-
vator molecule, and the differences are typically equal to 0.1%
novel epitope exposure or less as estimated with the urea-treated
unfolded mAb. In the second group, there was no recogniz-
able difference between the innovator mAb and the biosimilar
molecule. Since the relative variation of the ELISA is typically less
than 15%, this means that in all the regions tested, no more than
15% difference was observed. So far only a few biosimilar mAbs
tested belong to this group, underscoring the challenge to pro-
duce structurally high similar mAbs in biosimilar development.
In the third group, significant differences between the biosimilar
molecule and the innovator mAb were detected. A few biosimilar
mAbs were found to be in this group. In some cases where sig-
nificant differences were observed in the HOS, the corresponding
bioassays also detected loss of activity in stability testing (data not
shown). While it is difficult to predict the clinical consequences of
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APPLICATIONS IN BIOSIMILAR mAb DEVELOPMENT
For the development of biosimilar mAbs, comparability analysis
for biosimilarity is a major focus. Various analytical technolo-
gies and bioassays are needed to demonstrate comparability from
many aspects of the molecule including primary and secondary
structure, post-translational modifications especially glycosyla-
tion, bioactivity and protein (HOS). For protein HOS, current
technologies can only provide an average reading of the molec-
ular changes in the mAb population, changes in the specific
regions of the mAb cannot be obtained. In a recent publica-
tion from the FDA, the regulatory agency acknowledges the need
to develop novel technologies for protein conformational analy-
sis (US Food and Drug Administration, 2012). It is understood
that mAb Higher Order Structural changes in biosimilar mAbs
could raise the potential risk of immunogenicity or altered PK/PD
thus, impacting the safety and efficacy of the molecule. The anti-
body array technology described in this report could provide
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the biosimilar mAbs with the minor conformational differences,
it is obvious that the biosimilar mAbs with significant confor-
mational and bioassay differences cannot be developed clinically.
It is important to point out that while in some cases the bioas-
say results were correlated with the conformational findings, in
other cases, no bioassay differences were observed yet signif-
icant differences were observed by the antibody array testing.
This is understandable because bioassays are mainly measuring
changes in the CDR regions or the Fv domains, whereas the anti-
body arrays provide a systematic measurement throughout the
molecule including the Fc region of the mAb, and this additional
capability of the antibody array provides valuable information on
the conformational comparability in the Fc region which could
be important for the immunogenicity potential of the biosimilar
mAb. Since the antibody array ELISA is an easy to use method, it
might be worth the effort to implement this method when select-
ing cell lines producing the biosimilar mAb so that a molecule
with HOS that is highly similar to the innovator molecule could
be selected to ensure a successful clinical development. The fact
that a few biosimilar mAbs under development showed highly
similar HOS suggested that this is a possible approach.
ANTIBODY ARRAY PROVIDES DETAILED STRUCTURAL INFORMATION
Because of the antibody specificity, changes observed by the
antibody array can be assigned to a very specific region of the
molecule. In Figure 7, the 3-D structure showed one region that
has been detected with differences in the mAb stability testing.
With this structural information for biosimilars, a method is
available that can be used in many stages of development. The
most valuable application will be in the cell line development
because it is possible to screen multiple clones and select the one
that is most close to the innovator molecule in many aspects of
the attributes including its HOS. Since the mAb purification pro-
cess and formulation can also impact the specific HOS the mAb
will assume, this ELISA-based conformational analysis can also be
used in process and formulation development.
NOVEL mAb HIGHER ORDER STRUCTURE ANALYSIS
It is obvious that there is a difficulty in the development of an
antibody array for novel mAbs conformational analysis because
each mAb will have different CDR regions. For the constant
regions of light chain and heavy chain, high amino acid sequence
homology exists (>95%), therefore, one set of polyclonal anti-
bodies in these two regions will provide a good coverage for any
novel mAbs (Wang et al., 2009). For the Fv regions, a platform-
based approach seems count-intuitive. However, when multiple
mAb sequences were aligned and compared, it is obvious that
even in the Fv regions, about 2/3 of the amino acid sequence is
conserved (Wang et al., 2009). The major differences only occur
in the three CDR regions of the light chain and heavy chain,
respectively. Furthermore, even in the CDR regions, there is also
certain level of homology; therefore, the sequence analysis pro-
vides the basis for an approach for antibody array-based novel
mAbHOS analysis. For the constant region of a novel mAb (2/3 of
the whole mAb), a platform-based approach was taken. For the Fv
region, in each overlapping peptide segment (for example amino
acid sequence 1–30), the polyclonal antibodies corresponding to 8
FIGURE 7 | Three-dimensional assignment of changes detected with
the antibody array ELISA. Vector NTI Express software from Life
technology was used to display the mAb three-dimensional structure based
on the information from the protein structure database. The fragment
highlighted in yellow is one representative peptide that was used to raise
the specific antibody. Epitope exposure changes detected by this antibody
therefore, could be assigned to this specific region because the high
specificity of the antibodies generated.
FIGURE 8 | Constant region analysis of novel mAbs under clinical
development. Seven mAbs under clinical development were tested for
their surface epitope exposure, the common set of antibodies raised
against Herceptin constant region was used for the testing.
different mAbs with known sequences were combined to provide
coverage for the possible variations in a novel mAb (for exam-
ple the first antibody for the variable region of the light chain of
Avastin, Rituxan, Herceptin, Humira, Erbitux etc. will be com-
bined). The reasoning here is that even if not matched exactly
for a novel mAb, the polyclonal antibodies generated from the
eight different mAbs will provide a good approximate for a novel
mAb and actual testing indicated that this is indeed the case.
In Figure 8, the constant regions of 7 novel mAbs under clin-
ical development were tested, among them mAb3, mAb4, and
mAb7 were known to have failed during the clinic. It seems that
for the failed mAb, significant C-terminal epitope exposures were
observed (as indicated by the red bar). Since this is a small sample
pool, it is difficult to gauge the predictive value of this antibody
array for novel mAb clinical outcome but it is an area that future
effort will be focused on.
www.frontiersin.org August 2013 | Volume 4 | Article 103 | 7
Wang et al. Antibody array for biosimilar development
CONCLUSIONS
The antibody array ELISA has been used for the conformational
analysis of biosimilar as well as novel mAbs under development.
The findings in biosimilar mAbs suggested that this antibody
array technology can detect “conformational impurities” that are
correlated with bioassay or stability findings. More importantly,
this antibody array technology can detect conformational dif-
ferences that sometimes may not be able to be detected with
other current analytical technologies or bioassays, suggesting a
complementary value in biosimilar as well as novel mAb devel-
opment. It is possible to implement this assay in biosimilar mAb
cell line development to ensure that highly similar mAbs with
conformational comparability could be selected. In novel mAb
development, it was shown that the InnoBridge ELISA kit could
be used to measure conformational comparability of mAbs under
clinical development. Furthermore, a small sample of mAbs that
were known to have failed during clinical development seem to
have more C-terminal epitope exposure compared with those
that have made it to the market. Finally in the mAb constant
region, whether it is mAbs on the market or novel mAbs under
development, no two mAbs gave identical conformational pat-
tern even though the amino acid sequences are almost identical.
This underscores a point that is taken as fact in the biosimilar
field, that “process is the product.” It also indicates the challenge
to develop biosimilar mAbs because the detailed process infor-
mation from the innovator companies is not known for the most
part. As more sensitive and accurate analytical technologies for
mAb characterization are developed and implemented, the devel-
opment of biosimilar as well as novel mAbs will be put on a solid
scientific base.
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